Continuing to confront COPD international patient survey: Economic impact of COPD in 12 countries

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Foo, Jason ^a   Landis, Sarah H ^a   Maskell, Joe ^a   Oh, Yeon Mok ^b   Van Der Molen, Thys ^c   Han, MeiLan K ^d   Mannino, David M ^e   Ichinose, Masakazu ^f   Punekar, Yogesh ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b University of Ulsan College of Medicine   (South Korea)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^f TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; INFLUENZA VACCINE; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYGEN; ROFLUMILAST; SHORT ACTING DRUG; XANTHINE DERIVATIVE;

ADULT; AGED; ARTICLE; BRAZIL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE EXACERBATION; ECONOMIC EVALUATION; FEMALE; FRANCE; GERMANY; HEALTH CARE PERSONNEL; HEALTH STATUS; HEALTH SURVEY; HOSPITALIZATION COST; HUMAN; INFLUENZA VACCINATION; ITALY; JAPAN; MALE; MEXICO; NETHERLANDS; OXYGEN THERAPY; POPULATION RESEARCH; PRODUCTIVITY; RUSSIAN FEDERATION; SELF REPORT; SOUTH KOREA; SPAIN; UNITED KINGDOM; UNITED STATES; COST OF ILLNESS; ECONOMICS; HEALTH CARE COST; HEALTH CARE PLANNING; HOSPITALIZATION; MIDDLE AGED; PREVALENCE; PROCEDURES;

AGED; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HEALTH SURVEYS; HOSPITALIZATION; HUMANS; ITALY; MALE; MIDDLE AGED; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPUBLIC OF KOREA; RUSSIA; UNITED KINGDOM; UNITED STATES;

EID: 84964573662     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152618     Document Type: Article

References (25)

1. The Global Initiative for Chronic Obstructive Lung disease (GOLD) revised 2014 www.goldcopd.com.
2. Agusti AG: COPD, a multicomponent disease: implications for management. Respir Med 2005, 99:670-682.
3. World Health Organisation: Burden of COPD. Last accessed 04 February 2015. http://www.who.int/respiratory/copd/burden/en/
4. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Globaland regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380:2095-2128. doi: 10.1016/S0140-6736(12)61728-0 PMID: 23245604
5. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380:2197-2223. doi: 10.1016/S0140-6736(12)61689-4 PMID: 23245608
6. Wouters EF: Economic analysis of the Confronting COPD survey: an overview of results. Respir Med 2003, 97(SupplC):S3-14. PMID: 12647938
7. Polatli M, Ben Kheder A, Wali S, Javed A, Khattab A, Mahboub B, et al. (2012) Chronic obstructive pulmonary disease and associated healthcare resource consumption in the Middle East and North Africa: The BREATHE study. Respir Med. 106(Suppl. 2): S75-S85. doi: 10.1016/S0954-6111(12)70016-1 PMID: 23290706
8. Fletcher MJ, Upton J, Taylor-Fishwick J, Buist SA, Jenkins C, Hutton J, et al. COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health 2011; 11:612. doi: 10.1186/1471-2458-11-612 PMID: 21806798
9. Chapman K, Mannino D, Soriano J, Vermeire P, Buist A, Thun M, et al: Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006, 27:188-207. PMID: 16387952
10. Rennard S, Decramer M, Calverley PMA, Pride NB, Soriano JB, Vermeire PA, Vestbo J. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J. 2002; 20:799-805. PMID: 12412667
11. Landis SH, Muellerova H, Mannino DM, Menezes AM, Han MK, van der Molen T, et al. Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012-2013. Int J Chron Obstruct Pulmon Dis. 2014; 9:597-611. doi: 10.2147/COPD.S61854 PMID: 24944511
12. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999; 54:581-586. PMID: 10377201
13. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009; 34:648-654. doi: 10.1183/09031936.00102509 PMID: 19720809
14. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993; 4:353-365. PMID: 10146874
15. de Miguel-Diez J, Carrasco-Garrido P, Rejas-Gutierrez J, Martin-Centeno A, Gobartt-Vazquez E, Hernandez-Barrera V, et al. The influence of heart disease on characteristics, quality of life, use of health resources, and costs of COPD in primary care settings. BMC Cardiovasc Disord 2010; 10:8. doi: 10.1186/1471-2261-10-8 PMID: 20167091
16. Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14:171-189. PMID: 10154656
17. Kigozi J, Jowett S, Lewis M, Barton P, Coast J. Estimating productivity costs using the friction cost approach in practice: a systematic review. Eur J Health Econ 2016; 17:31-44. doi: 10.1007/s10198-014-0652-y PMID: 25387561
18. Srivastava K, Thakur D, Sharma S, Punekar YS. Systematic Review of Humanistic and Economic Burden of Symptomatic Chronic Obstructive Pulmonary Disease. Pharmacoeconomics 2015; 33(5):467-88. doi: 10.1007/s40273-015-0252-4 PMID: 25663178
19. Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged > 18 Years in the United States for 2010 and projections through 2020. Chest 2015; 147:31-45. doi: 10.1378/chest.14-0972 PMID: 25058738
20. Miravitlles M, Murio C, Guerrero T, Gisbert R, on behalf of the DAFNE Study Group. Costs of Chronic Bronchitis and COPD. A 1-Year Follow-up Study. Chest 2003; 123:784-791. PMID: 12628879
21. Nishimura S, Zaher C. Cost impact of COPD in Japan: Opportunities and challenges? Respirology 2004; 9:466-473. PMID: 15612957
22. Kim C, Yoo KH, Rhee CK, Yoon HK, Kim YS, Lee SW, et al. Health care use and economic burden of patients with diagnosed chronic obstructive pulmonary disease in Korea. Int J Tuberc Lung Dis 2014; 18:737-743. doi: 10.5588/ijtld.13.0634 PMID: 24903947
23. Muka T, Imo D, Jaspers L, Colpani V, Chaker L, van der Lee SJ, et al. The global impact of non-communicable diseases on healthcare spending and national income: a systematic review. Eur J Epidemiol 2015; 30:251-277. doi: 10.1007/s10654-014-9984-2 PMID: 25595318
24. Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: A global systematic review. Pharmacoeconomics 2015; 33:811-831. doi: 10.1007/s40273-015-0268-9 PMID: 25787932
25. Chaker L, Falla A, van der Lee SJ, Muka T, Imo D, Jaspers L, et al. The global impact of non-communicable diseases on macro-economic productivity: a systematic review. Eur J Epidemiol 2015; 30:357-395. doi: 10.1007/s10654-015-0026-5 PMID: 25837965